Business Wire

ALL-IN-ON-GREEN

Share
All In On Green: Many Tonnes of Waste Flow Into the Sea From the World’s Rivers: a Danish Robot Minimises This Pollution

At least 70 cities in Europe can now prevent huge amounts of waste from ending up in the sea. This has been demonstrated in the city of Aarhus in Denmark, where the robot SeaProtectorOne, made by All In On Green, collected over 100,000 pieces of waste from the city’s river in just 20 months. The technology thus shows how much pollution the city is otherwise sending into the marine environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221211005006/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Many tonnes of waste flow into the sea from the world’s rivers: A Danish robot minimises this pollution (Photo: Business Wire)

Once waste enters the oceans, removing it is extremely difficult. This is why a Danish robotics invention is tackling the problem before it happens. The robot SeaProtectorOne is installed at the river mouth in Aarhus, where the river flows into the harbour and wider sea. The robot collects the waste—things like plastic cups, facemasks and pizza boxes—before it pollutes the sea. At the same time, it allows boats and other marine vessels to pass by.

SeaProtectorOne could also limit sea pollution from rivers in at least 70 other cities in Europe. This potential has been shown by thorough studies of the cities’ local conditions carried out by the team that has developed SeaProtectorOne. Kim Gulvad Svendsen, COO, Aarhus Municipality, readily shares his positive experience with this new weapon in the fight to prevent sea pollution.

“After the trial period, we were surprised at just how effective the robot was and by how much waste – especially plastic – it removed. This is plastic that will no longer end up in our marine environment. So the robot supports Aarhus Municipality’s sustainability efforts and above all, the UN’s global sustainable development goal no. 14: Life Below Water,” said Kim Gulvad Svendsen.

Every year, the amount of plastic waste that ends in the oceans is equivalent in weight to 57,000 blue whales. At least 90% of the plastic waste that floats around in the oceans, ends in the sea via river systems, according to the periodical Environmental Science.

“Once waste enters the sea it spreads quickly and is difficult to collect. Whereas the current in a river allows for the systematic filtering of waste in a limited area without disturbing fish or birds,” said Peter Grønkjær, Professor of Marine Biology at the Aarhus University.

Mads Tranders Nielsen from All In On Green is the man who invented SeaProtectorOne.

“In an ideal world, every citizen everywhere would learn to always put waste into a waste bin. But we don’t live in an ideal world. The idea for the robot came to me when I saw huge amounts of waste floating in a river in Melbourne. SeaProtectorOne has now shown its worth, even in Aarhus, one of Europe’s greenest cities. So, I’m looking forward to bringing this technology to the rest of the world for the benefit of the marine environment, fish and birds,” said Mads Tranders Nielsen from All In On Green.

Press Photos

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221211005006/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus

Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release

Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye